Showing results (1-10 of 84) with videos related to
Sort By:
Pageof 9
Journal of Managed Care & Specialty Pharmacy|August 24, 2022
Characterizing health plan evidence review practicesAri D Panzer, Daniel E Enright, Jen Graff, et al.Pharmacoepidemiology and Drug Safety|March 27, 2020
What types of real-world evidence studies do U.S. commercial health plans cite in their specialty drug coverage decisions?Ari D Panzer, Nikoletta M Margaretos, Rachel C Lai, et al.Journal of Managed Care & Specialty Pharmacy|February 25, 2023
Examining US commercial health plans' use of The Institute for Clinical and Economic Review's reports in specialty drug coverage decisionsJames D Chambers, Daniel E Enright, Ari D Panzer, et al.Journal of Managed Care & Specialty Pharmacy|November 24, 2021
Use of prescriber requirements among US commercial health plansKelly Lenahan, Ari D Panzer, Rebecca Gertler, et al.Journal of Managed Care & Specialty Pharmacy|March 29, 2023
The association between US Food and Drug Administration-expedited review designations and health plan specialty drug coverageAri D Panzer, Michael Ingham, Silas Martin, et al.Journal of Managed Care & Specialty Pharmacy|August 2, 2021
Limited role of patient input in specialty drug coverage policiesBrittany D'Cruz, Jennifer S Graff, Ari D Panzer, et al.The American Journal of Managed Care|October 18, 2019
Variation in US private health plans' coverage of orphan drugsJames D Chambers, Ari D Panzer, David D Kim, et al.Health Affairs (Project Hope)|November 5, 2019
Little Consistency In Evidence Cited By Commercial Plans For Specialty Drug CoverageJames D Chambers, Ari D Panzer, Elle F Pope, et al.The American Journal of Managed Care|September 20, 2023
Varied use of step therapy among Medicare Advantage plansNola B Jenkins, Donald E Nichols, Daniel E Enright, et al.Pharmacoeconomics|October 26, 2021
Is an Orphan Drug's Cost-Effectiveness Associated with US Health Plan Coverage Restrictiveness?James D Chambers, Nikoletta M Margaretos, Daniel E Enright, et al.Pageof 9